Priyanka Verma, PhDWashington University, St. Louis2022 MCM Pilot Study Award Targeting drug resistance in BRCA-mutant ovarian cancers by exploiting endogenous base damage Many ovarian cancers are caused by mutations in proteins that usually function to repair DNA damage. These cancer cells with accumulated DNA damage are targeted by PARP inhibitor therapies. Despite ovarian tumors showing […]
Read More
Dipanjan Chowdhury, PhDDana-Farber Cancer Institute OC130658: Noncoding RNAs as Prognostic and Predictive Biomarkers in BRCA 1/2-Mutated and Wildtype Epithelial Ovarian Cancer Patients with epithelial ovarian cancer that carry BRCA1 or BRCA2 mutations can successfully be treated with platinum chemotherapy and PARP inhibitors because the BRCA1/2 mutations cause a defect in DNA repair. This allows the […]
Read More
Srinivas Sridhar, PhDNortheastern University Targeted PARP Inhibitor Nanotherapy for Ovarian Cancer PARP inhibitor therapy has shown promising results in clinical trials for ovarian cancer, but oral administration of these drugs requires high doses leading to toxic side effects, and very little drug actually reaches the tumors. Dr. Sridhar and colleagues have synthesized nano-scale formulations of […]
Read More
Janet Sawicki, PhDLankenau Institute for Medical Research Utilizing HuR to Combat Chemotherapeutic Resistance in Ovarian Cancer The molecular basis underlying the range of ovarian cancer patient responses to chemotherapeutic agents is poorly understood. This project will address the urgent need to stratify ovarian cancer patients for therapy and enhance currently available treatment strategies. Recently, Dr. […]
Read More
Jeremy Stark, PhDBeckman Research Institute of the City of Hope Homology-Directed Repair Deficiency in Ovarian Cancer Cancer cells that are able to perform homology-directed repair (HDR) can be resistant to PARP inhibitor therapeutics, which are purposefully designed to cause DNA damage. Many ovarian cancers apparently lack the HDR pathway, and hence are likely to be […]
Read More
Lilie Lin, MDUniversity of Pennsylvania School of Medicine Pilot study of a novel PARP inhibitor PET tracer in patients with ovarian carcinoma Targeted agents such as poly-ADP ribose polymerase (PARP) inhibitors are actively being tested alone or in combination with chemotherapy or radiotherapy as promising treatments for ovarian cancer. However, not all patients will respond […]
Read More
Andrew Wilson, PhDVanderbilt University Prognostic Significance of TR3/NR4A1 Expression in Ovarian Cancer A key clinical problem in the management of advanced ovarian cancer is tumor resistance to traditional platinum drugs and to newer drugs that inhibit the PARP protein (PARPi). Dr. Wilson will investigate an innovative approach to improve the effects of platinum drugs and […]
Read More
Alvaro Monteiro, Ph.D.H. Lee Moffitt Cancer Center & Research InstituteTampa, FL, United States Project: Tackling PARP inhibitor resistance through functional proteomics Research Areas: Chemotherapy Resistance Summary:There has been significant progress in ovarian cancer treatment especially with the development and approval of PARP inhibitor drugs. Despite this progress, a sizable percentage of patients do not respond or stop […]
Read More